Medicure Inc. (CVE:MPH – Get Free Report) shares passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of C$1.14 and traded as low as C$1.13. Medicure shares last traded at C$1.13, with a volume of 1,100 shares traded.
Medicure Stock Performance
The company has a market cap of C$10.85 million, a PE ratio of -1.60 and a beta of 0.49. The stock has a 50 day simple moving average of C$1.14 and a two-hundred day simple moving average of C$1.14. The company has a debt-to-equity ratio of 6.34, a current ratio of 1.04 and a quick ratio of 1.28.
About Medicure
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
Further Reading
- Five stocks we like better than Medicure
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
